Recombinant Anti-EpCAM-CD3 Antibody not checked

ITabMed Co., Ltd.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
None yet
 
Trials
1 active
1 in total
Targets
 

What this is

How it works
How it works isn't classified yet
Tested for
Recurrent or Metastatic Solid Tumors
Main trialPhase 1
“Title: An Exploratory Study of A-337 in the Management of Malignant Solid Dose Escalation and Expansion Phases”In the company’s words, NCT06093698 on ClinicalTrials.gov

Other drugs for Recurrent or Metastatic Solid Tumors

All 266 drugs for Recurrent or Metastatic Solid Tumors

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 1Not yet recruiting 30 Jun 2026 An Exploratory Study of A-337 in the Management of Malignant Solid Dose Escalation and Expansion Phases
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow Recombinant Anti-EpCAM-CD3 Antibody

Following is part of Solo: you see every change to Recombinant Anti-EpCAM-CD3 Antibody the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in